| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5685153 | Advances in Chronic Kidney Disease | 2017 | 8 Pages |
Abstract
Targeted therapies that act via unique molecular pathways and interfere with cancer cell growth and tumor progression have dramatically changed the cancer treatment paradigm. However, although, ideally, these therapies intend to target only cancer cells, they do often affect nonmalignant tissue. Numerous renal side effects have been reported to date. This article will review clinical presentation, presumed pathophysiology, and treatment of kidney side effects of targeted therapies. Feasibility of the continuation of cancer therapy despite renal toxicity will also be addressed.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Joannie Lefebvre, Ilya G. Glezerman,